Table 1. Summary of the seven genome-wide association studies of colorectal cancer (9,254 cases and 18,386).
| Series | Study setting | Study centre | Sampling | No. cases | No. controls |
|---|---|---|---|---|---|
| CCFR1 | Colon Cancer Family Registry | University of Southern California | Recently diagnosed cases reported to population-based cancer registries in the USA (Seattle Familial Colorectal Cancer Registry). Canada (Ontario Familial Cancer Registry) and Australia (Australasian Colorectal Cancer Family Study). Population-based controls. | 1,290 | 1,055 |
| CCFR2 | Colon Cancer Family Registry | University of Southern California | Recently diagnosed cases reported to population-based cancer registries in the USA (Seattle Familial Colorectal Cancer Registry, Mayo Clinic Cooperative Family Registry for Colon Cancer Studies, USC Consortium Colorectal Cancer Family Registry, University of Hawaii Colorectal Cancer Family Registry). Canada (Ontario Familial Cancer Registry) Australia (Australasian Colorectal Cancer Family Study). Unaffected family controls. | 796 | 2,236 |
| COIN | COIN trial: Multicentre study of cetuximab and other therapies in metastatic CRC. Controls were unselected blood donors | Cardiff University | Cases recruited as a clinical-based series and controls as population-based series. | 2,244 | 2,162 |
| FINLAND | Finnish Colorectal Cancer Predisposition Study | Helsinki University | Cases requited through Finnish Hospitals and Finnish Cancer Registry. Population-based controls from FINRISK, Health 2000, Finnish Twin Cohort and Helsinki Birth Cohort Studies. | 1,172 | 8,266 |
| UK1 | CORGI (colorectal Tumour Gene Identification Consortium) | Oxford University | Cases enriched for family history of CRC, ascertained through UK clinical genetics clinics. Spouse controls with no personal history or family history of CRC. | 940 | 965 |
| Scotland1 | COGS (Colorectal Cancer Susceptibility Study) | Edinburgh University | Scottish population-based incidence cases aged <55 at diagnosis. Population-based controls frequency matched by area of residence. Scotland | 1,012 | 1,012 |
| VQ58 | Cases: VICTOR, post treatment stager of a phase III, randomised trial of rofecoxib (VIOXX) in patients after potentially curative therapy. QUASAR2, multi-centre study of capectibine±bevacizumb as adjuvant treatment. 1958 Birth Cohort controls |
Oxford University | Cases recruited as a clinical-based series and controls as population-based series. | 1,800 | 2,690 |